FDA accepts NDA for Incyte/Novartis drug; NPS snags rights to two GSK programs;

@FierceBiotech: Insmed shares crater as FDA puts a clamp on Ph3 CF study. Report | Follow @FierceBiotech

@JohnCFierce: Sometimes wonder when/if a Big Pharma would do a Valeant, punt early-stage research, pick up good stuff after PoC. Pfizer? | Follow @JohnCFierce

@RyanMFierce: BioClinica 2Q earnings out, service revenue up 8.7% News $BIOC | Follow @RyanMFierce

@MaureenFierce: Which 3 Pharmas are tops for cardiology meds? $PFE is one, according to doctors. Article | Follow @MaureenFierce

> The FDA has accepted Incyte's NDA for its lead compound, ruxolitinib (INCB18424/INC424), a potential treatment for patients with myelofibrosis. The treatment has been developed under a collaboration deal the biotech struck with Novartis. Release

> NPS Pharma has amended its licensing deal with GlaxoSmithKline, snagging the rights to two compounds--SB-423557 and SB-423562--for autosomal dominant hypocalcemia with hypercalciuria, a rare endocrine disorder. Article

> Shares of Ista Pharmaceuticals were depressed by the news that regulators at the FDA don't believe that the company submitted adequate data to support the approval of a larger dose of its eye drug Bromday. Story

> Quintiles named Dr. Jeffrey A. Spaeder as its chief medical and scientific officer. Release

> Scientists believe they have found a marker indicating genetic predisposition to tuberculosis, bringing closer the day when doctors can adjust therapies to individuals based on their genotype. Article

> Embedded in a feature story on diagnostic microchips, Texas CEO magazine makes a compelling case for the reasons behind biomarkers' seeming inability to transfer quickly enough from lab to clinic. Report

> 'Systems biology' could find earliest signs of breast cancer. Story

Pharma News

@FiercePharma: Wockhardt finally unloads nutrition unit, to Danone. French giant also said to be eyeing Pfizer's nutrition biz. Story | Follow @FiercePharma

> Hedge fund swoops in with $38M Amag bid. News

> Government watchdog attacks FDA conflicts plan. More

> Merck, Norvatis top drug approval rankings. Article

> Read Pfizer CEO'slips: No large deals. Story

> Study: Antipsychotic doesn't work for vet's PTSD. Report

Drug Delivery News

> More companies going with prefilled syringes ahead of flu season. Item

> Growth factor delivery method makes long-lasting blood vessels. More

> Pfizer completes sale of Capsugel delivery unit. Report

> OctoPlus tries to get drug-delivery tentacles into generics. Story

> Nanomaterial improves on VEGF for blood-vessel growth. News

> Depomed inks another deal for AcuForm, this time with Ironwood. Article

Medical Device News

> FMD speaks with Cell>Point's David Rollo. Item

> Berlin Heart pediatric offering could soon help US patents. Piece

> Restoration Robotics raises $41M. Story

> BD, Lab21 team on Aspergillus assay. News

> Fresenius buys US competitors. Article

> Ellipse Technologis completes $17.6M Series C financing. More

> Becton Dickson sees strong Q3. Report

And Finally... It's always good to have a sense of humor in the face of illness, but researchers say that laughter may not be the best medicine for COPD. Release

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.